KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Deferred Taxes: 2016-2023

Historic Deferred Taxes for Moderna (MRNA) over the last 5 years, with Dec 2023 value amounting to $901.0 million.

  • Moderna's Deferred Taxes rose 68.57% to -$33.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $901.0 million, marking a year-over-year increase of 255.88%. This contributed to the annual value of $901.0 million for FY2023, which is 255.88% up from last year.
  • Per Moderna's latest filing, its Deferred Taxes stood at $901.0 million for FY2023, which was up 255.88% from -$578.0 million recorded in FY2022.
  • In the past 5 years, Moderna's Deferred Taxes ranged from a high of $901.0 million in FY2023 and a low of -$578.0 million during FY2022.
  • Its 3-year average for Deferred Taxes is $1.7 million, with a median of -$318.0 million in 2021.
  • Its Deferred Taxes has fluctuated over the past 5 years, first plummeted by 81.76% in 2022, then spiked by 255.88% in 2023.
  • Moderna's Deferred Taxes (Yearly) stood at -$1.0 million in 2019, then reached -$318.0 million in 2021, then crashed by 81.76% to -$578.0 million in 2022, then spiked by 255.88% to $901.0 million in 2023.